PMID- 24302666
OWN - NLM
STAT- MEDLINE
DCOM- 20141114
LR  - 20181202
IS  - 1479-6821 (Electronic)
IS  - 1351-0088 (Linking)
VI  - 21
IP  - 2
DP  - 2014 Apr
TI  - Sorafenib in the treatment of radioiodine-refractory differentiated thyroid 
      cancer: a meta-analysis.
PG  - 253-61
LID - 10.1530/ERC-13-0438 [doi]
AB  - The advent of biologically targeted agents and increased understanding of thyroid 
      carcinogenesis have generated much interest in the development of biologically 
      targeted therapeutic agents for thyroid cancer. Among them, sorafenib is the most 
      commonly studied drug. The current meta-analysis was carried out to estimate the 
      efficacy and safety of sorafenib administered in radioiodine-refractory 
      differentiated thyroid cancer patients. An electronic search was conducted using 
      PubMed/MEDLINE and EMBASE. Statistical analyses were carried out using either 
      random-effects or fixed-effects models according to heterogeneity. All the 
      statistical analyses were carried out using the Stata version 12.0 software. 
      Seven eligible studies were identified. The final results indicated that 22% of 
      the patients (95% CI: 15-28) achieved a partial response. Hand-foot syndrome, 
      diarrhea, fatigue, rash, weight loss, and hypertension were the most frequently 
      observed adverse effects (AEs) associated with sorafenib use and the incidence of 
      these AEs (all grades) was 80% (95% CI: 68-91), 68% (95% CI: 59-77), 67% (95% CI: 
      57-78), 66% (95% CI: 50-82), 52%(95% CI: 33-72), and 31% (95% CI: 21-42) 
      respectively. Sixty-two percent (95% CI: 36-89) patients required dose reductions 
      due to toxicity of sorafenib. As far as PR and AEs are concerned, the results of 
      this meta-analysis indicate that sorafenib has a modest effect in patients with 
      radioiodine-refractory differentiated thyroid cancer and the high incidence of 
      AEs associated with this agent may affect the quality of patients' lives. Though 
      the use of sorafenib in the treatment of radioiodine-refractory differentiated 
      thyroid cancer is considered promising by most physicians working in this field, 
      more effective agents with less toxicity and cost are still needed.
FAU - Shen, Chen-Tian
AU  - Shen CT
AD  - Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth 
      People's Hospital, 600 Yishan Road, Shanghai 200233, People's Republic of China.
FAU - Qiu, Zhong-Ling
AU  - Qiu ZL
FAU - Luo, Quan-Yong
AU  - Luo QY
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20140227
PL  - England
TA  - Endocr Relat Cancer
JT  - Endocrine-related cancer
JID - 9436481
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Iodine Radioisotopes)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
CIN - Endocr Relat Cancer. 2014 Apr;21(2):L3-4. PMID: 24639563
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Drug Resistance, Neoplasm
MH  - Humans
MH  - Iodine Radioisotopes/therapeutic use
MH  - Niacinamide/adverse effects/*analogs & derivatives/therapeutic use
MH  - Phenylurea Compounds/adverse effects/*therapeutic use
MH  - Protein Kinase Inhibitors/adverse effects/*therapeutic use
MH  - Sorafenib
MH  - Thyroid Neoplasms/*drug therapy
OTO - NOTNLM
OT  - differentiated thyroid cancer
OT  - meta-analysis
OT  - molecular targeted therapy
OT  - sorafenib
OT  - tyrosine kinase inhibitors
EDAT- 2013/12/05 06:00
MHDA- 2014/11/15 06:00
CRDT- 2013/12/05 06:00
PHST- 2013/12/05 06:00 [entrez]
PHST- 2013/12/05 06:00 [pubmed]
PHST- 2014/11/15 06:00 [medline]
AID - ERC-13-0438 [pii]
AID - 10.1530/ERC-13-0438 [doi]
PST - epublish
SO  - Endocr Relat Cancer. 2014 Feb 27;21(2):253-61. doi: 10.1530/ERC-13-0438. Print 
      2014 Apr.